Mar 25,2021

Virtual Human Interaction Lab at Stanford University Collaborates with MyndVR to Study Impact of Virtual Reality on Older Adults, with Support from AT&T 5G Technology

The Virtual Human Interaction Lab (VHIL) at Stanford University, the pioneering lab focused on the psychological and behavioral effects of virtual reality, announced a new study in collaboration with MyndVR, the leading provider of VR solutions for older adults. The Study will examine how older adults’ use of VR affects their psychological well-being and their attitudes toward new technologies.

PRODUCT

#virtual reality

View Analyst & Ambassador Comments
Go to original news
Jun 03,2021

BehaVR Partners With Reach’s National “Save Moms” Campaign to Improve Maternal Health in Vulnerable Populations

BehaVR, a digital therapeutics company that aims to liberate people from stress, anxiety and fear though the power of virtual reality, today announced a partnership with Save Moms — the national maternal mortality and morbidity prevention campaign directed by Reach, a 501(c)(3) global social impact organization — in support of expectant mothers in underserved communities. BehaVR will provide NurtureVR, a first-of-its-kind virtual reality program for expectant moms, to 5,000 low-income and otherwise marginalized families, along with a portion of sales proceeds, to support Reach’s efforts to provide maternal healthcare resources and education to expectant moms at higher risk for complications during and after pregnancy.

PRODUCT

#virtual reality

#rpm

View Analyst & Ambassador Comments
Go to original news
Oct 20,2021

Luminopia Announces FDA Approval of Digital Therapeutic to Improve Vision in Children with Lazy Eye

Luminopia, a digital therapeutics company, today announced that the U.S. Food and Drug Administration (FDA) has granted de novo premarket approval for Luminopia One as a prescription therapy to improve vision in children with amblyopia (lazy eye), the leading cause of vision loss in children. Luminopia One is indicated for improvement in visual acuity in children with amblyopia, aged 4-7, associated with anisometropia and/or with mild strabismus, having received treatment instructions as prescribed by a trained eye-care professional.

REGULATORY FDA

#virtual reality

View Analyst & Ambassador Comments
Go to original news
Oct 21,2021

Sumitomo Dainippon Pharma inks deal for VR-based DTx with BehaVR

Sumitomo Dainippon Pharma Co. in Japan and US-based behavioural health firm BehaVR have signed definitive agreements to develop and market general wellness products and prescription digital therapeutics for the treatment of major mental health disorders. The companies initially collaborated in June last year. They jointly developed a wellness product for those experiencing "stressful, fearful and overwhelming" feelings in a social setting. Under their recently signed deals, Sumitomo will fund the development and commercialisation of three novel virtual reality-based therapies for the treatment of social anxiety disorder, generalised anxiety disorder and major depressive disorder. It pledged to pay BehaVR $5 million in upfront payments; up to $18 million in development milestone and R&D support payments, on top of commercial and operational support fees; and up to $140 million in milestone payments conditional upon commercial success.

COLLABORATION PARTNERSHIP

#r&d

#virtual reality

View Analyst & Ambassador Comments
Go to original news
Nov 16,2021

FDA Authorizes Marketing of Virtual Reality System for Chronic Pain Reduction

The U.S. Food and Drug Administration today authorized marketing of EaseVRx, a prescription-use immersive virtual reality (VR) system that uses cognitive behavioral therapy and other behavioral methods to help with pain reduction in patients 18 years of age and older with diagnosed chronic lower back pain.

REGULATORY FDA

#virtual reality

#cbt

View Analyst & Ambassador Comments
Go to original news
Dec 10,2021

HypnoVR raises €4.5M in Series A

French digital therapeutics firm HypnoVR has raised €4.5 million in Series A funding for its virtual reality-based medical hypnosis solution for pain and anxiety. The round was led by Theodorus, the Banque des Territoires operating for the French state as part of the Investments for the Future Programme, Akiles and Capital Grand Est via Alsace Création. HypnoVR will use the funds to accelerate its international roll-out and extend the scope of application of its solution.

FUNDING SERIES A

#virtual reality

View Analyst & Ambassador Comments
Go to original news
Dec 16,2021

Smileyscope Takes its Virtual Reality Digital Therapeutics Platform to the Next Level With the Power of Mindfulness

Australia- and New York-based, Smileyscope Holding Inc (Smileyscope) is a global pioneer in virtual reality (VR) therapeutics, and they welcome the internationally renowned mindfulness thought leader Craig Hassed OAM onto its platform enabling users to enjoy the immersive power of meditation.

PRODUCT

#virtual reality

View Analyst & Ambassador Comments
Go to original news
Dec 16,2021

Jolly Good to study VR therapy for chronic pain in Japan

Japanese medical device maker Jolly Good and the Pain Center at the Aichi Medical University Hospital will conduct a study on the efficacy of virtual reality-based therapy for chronic pain. It was in April last year that Jolly Good set up its digital therapeutics division, which involves a team of psychiatrists, pharmaceutical strategy specialists, and other DTx specialists. Through this, the company is expanding to cover multiple mental illnesses and lifestyle-related diseases. Jolly Good has been known for providing VR for medical training.

PRODUCT

#virtual reality

View Analyst & Ambassador Comments
Go to original news
Feb 24,2021

AppliedVR Completes Pivotal Trial Finding Virtual Reality Is a Holistic Treatment for Chronic Pain

AppliedVR, a pioneer advancing the next generation of digital medicine, today announced results from its pivotal randomized controlled trial (RCT), evaluating virtual reality (VR) therapy for treating chronic pain at home. The study, which was published in Journal of Medical Internet Research (JMIR), found that AppliedVR’s EaseVRx device produced “clinically meaningful” improvement in multiple pain outcomes, and had high participant satisfaction and engagement.

CLINICAL STUDY

#virtual reality

View Analyst & Ambassador Comments
Go to original news
Dec 02,2021

MINDMAZE AND CHUV RECEIVE INNOSUISSE INNOVATION GRANT TO DEVELOP NOVEL AI VR SOLUTION TO TRAIN ATTENTION IN ACQUIRED BRAIN INJURY

MindMaze Healthcare, the global leader in digital neuro-therapeutics solutions with a mission to accelerate the brain’s ability to recover, learn and adapt, and the Centre Hospitalier Universitaire Vaudois (CHUV), today announced that they have won the prestigious Innosuisse Grant to develop and study MindFocus, an innovative, immersive, artificial intelligence (AI)-driven virtual reality (VR) solution for cognition in brain damaged patients.

PRODUCT

#virtual reality

View Analyst & Ambassador Comments
Go to original news
Subscribe to VIRTUAL REALITY